Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24577909 | 0.90 | L3MBTL1 (0.52) | L3MBTL1SMN1; SMN2MAPTPOLBALDH1A1 | |
| SCHEMBL11598668 | 0.80 | L3MBTL1 (0.77) | L3MBTL1SMN1; SMN2MAPTPOLBALDH1A1 | |
| SCHEMBL8860545 | 0.80 | L3MBTL1 (0.77) | L3MBTL1SMN1; SMN2MAPTPOLBALDH1A1 | |
| SCHEMBL1007939 | 0.80 | L3MBTL1 (0.59) | L3MBTL1SMN1; SMN2MAPTPOLBALDH1A1 | |
| SCHEMBL1008219 | 0.79 | KDM4E (0.52) | L3MBTL1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL31269932 | 0.78 | L3MBTL1 (0.62) | L3MBTL1SMN1; SMN2MAPTPOLBALDH1A1 | |
| SCHEMBL31269835 | 0.78 | L3MBTL1 (0.62) | L3MBTL1SMN1; SMN2MAPTPOLBALDH1A1 | |
| SCHEMBL31270000 | 0.77 | L3MBTL1 (0.66) | L3MBTL1SMN1; SMN2MAPTPOLBALDH1A1 | |
| SCHEMBL2852219 | 0.77 | L3MBTL1 (0.65) | L3MBTL1SMN1; SMN2MAPTPOLBALDH1A1 | |
| SCHEMBL1007439 | 0.76 | L3MBTL1 (0.95) | L3MBTL1SMN1; SMN2MAPTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105488-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | CHLORION PHARMA, INC. (CA) | 2011-05-05 | — | — | US | claimed |
| CN-102036956-A | Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain | CHLORION PHARMA INC | 2011-04-27 | — | — | CN | claimed |
| EP-2268616-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | Chlorion Pharma, Inc. (CA) | 2011-01-05 | — | — | EP | claimed |
| WO-2009114950-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | CHLORION PHARMA, INC. (CA) | 2009-09-24 | — | — | WO | claimed |
| US-20110105488-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | CHLORION PHARMA, INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| US-20110105488-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | CHLORION PHARMA, INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| WO-2009114950-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | CHLORION PHARMA, INC. (CA) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105488-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | PAM, PNN, NOD1 | L3MBTL1 3671/4885SMN1; SMN2 1184/4885MAPT 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.